Details Basic Details Date Friday, August 25, 2017 Type Presentation Medical Product aripiprazole combined oral contraceptive (COC) gadolinium-based contrast agent (GBCA) olanzapine Ranexa ranolazine risperidone Health Outcome(s) stroke, venous thromboembolism (VTE), seizure Materials OverviewPrimer on Sentinel Inferential QueriesAntipsychotics and Stroke RiskVenous Thromboembolism (VTE) After Continuous or Extended Cycle Oral Contraceptive UseRisk of Seizures Associated with RanolazineContrast and Non-Contrast Magnetic Resonance Imaging (MRI) and Risk for Same Day Seizure Additional Information Information Host 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management Related Assessment(s) Sentinel Drug Study: Ranexa (ranolazine) & Seizure Sentinel Drug Study: Continuous or Extended Cycle Oral Contraceptives & Venous Thromboembolism (VTE) Sentinel Drug Study: Antipsychotic Agents (Including Haloperidol Injection) & Stroke Contributors Presenter(s) Michael D. Nguyen, Judith C. Maro, Lockwood G. Taylor, David Moeny, Efe Eworuke, Steven Bird